RGN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Systems RevenueRepligen’s business mixes recurring consumables with higher‑value equipment and analytics, creating durable revenue cadence tied to customer manufacturing runs. Consumables provide repeatable demand and stickiness, while systems drive long‑cycle customer engagement and cross‑sell opportunities.
Margin Expansion And Return To ProfitabilityRecent material margin expansion and return to TTM profitability signal improved operational leverage and pricing mix. Sustained mid‑20% EBITDA‑class margins (TTM ~23%) support free cash generation and fund R&D, though continued focus on cost discipline is needed to lock in gains.
Strong Liquidity And Cash GenerationLarge cash balance plus consistent positive operating and free cash flow (FCF ~80% of net income TTM) provides strategic optionality. This liquidity underpins M&A, the China OEM rollout, transformation investments and cushions timing volatility in capital equipment cycles.
Bears Say
Uneven Multi‑year Revenue/margin TrajectoryRepligen has shown stop‑start revenue and margin performance across recent years, which complicates medium‑term forecasting and suggests sensitivity to program timing, modality shifts and customer mix. Inconsistent recovery raises execution risk versus past peak profitability.
Capital Equipment Timing RiskA meaningful portion of revenue is tied to equipment and systems that depend on customer facility readiness and project timing. Lumpy order flow magnifies quarter‑to‑quarter volatility, can delay margin leverage from scale, and makes revenue visibility contingent on external project execution.
Competitive Pressure And China Localization LagIntensifying local competition in China forces localization investments and delays benefit capture until OEM partner ramps. This creates pricing and share risks in a high‑growth APAC market and requires sustained capex and operational focus to defend long‑term market position.
Repligen News
RGN FAQ
What was Repligen’s price range in the past 12 months?
Currently, no data Available
What is Repligen’s market cap?
Repligen’s market cap is CHF6.67B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Jul 28, 2026 which is in 6 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on May 05, 2026. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.312 by $0.078.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.36.
How many shares outstanding does Repligen have?
Currently, no data Available
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.39 in its last earnings report, beating expectations of $0.312. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in CH:RGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF134.61 (― Downside)
CHF134.61 (― Downside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.76%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGN Stock 12 Month Forecast
Average Price Target
$134.61
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―